VALIUM (diazepam) by Viatris (2) is mechanism of action although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (gaba) receptors of the a-type (gaba a ). First approved in 1963.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
Valium (diazepam) is a benzodiazepine small molecule approved in 1963 for seizure management, anxiety, and muscle relaxation. It works by enhancing GABA-A receptor activity in the central nervous system, increasing chloride ion influx to suppress neuronal depolarization and prevent seizure propagation. The drug represents a foundational CNS therapeutic class with over 60 years of clinical use.
Mature product with minimal Part D volume signals organizational focus on lifecycle management and cost containment rather than growth initiatives.
Mechanism of Action Although the precise mechanism by which diazepam exerts its antiseizure effects is unknown, animal and in vitro studies suggest that diazepam acts to suppress seizures through an interaction with γ-aminobutyric acid (GABA) receptors of the A-type (GABA A ). GABA, the major…
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on VALIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Valium offers limited growth opportunity given the LOE trajectory and zero linked open positions, making it a transitional or defensive portfolio assignment. Career development is best suited for professionals seeking experience in lifecycle management, generic defense, or managed care navigation rather than commercial growth.